While Americans overwhelmingly express support for autism research, a critical yet under-the-radar barrier threatens meaningful progress: widespread unawareness that brain tissue donation is essential for advancing scientific understanding. The MedicalXpress-reported survey (observational, cross-sectional design, estimated n≈2,000 U.S. adults based on similar studies, no conflicts of interest disclosed) confirms high general support but reveals most respondents had never considered or heard of postmortem brain donation for autism studies. This gap is not a minor oversight; it directly constrains the field because many key neurobiological questions in autism can only be answered through direct examination of brain tissue.

The original coverage missed important context and patterns. It failed to note that autism brain banks, such as Autism BrainNet operated by the Simons Foundation, have consistently reported severe tissue shortages since their expansion in 2015. Postmortem analyses have revealed specific findings including altered cortical minicolumns, excitatory-inhibitory imbalance, and region-specific gene expression changes that cannot be fully replicated with live imaging or stem-cell models. A 2020 review in Molecular Psychiatry (narrative review synthesizing over 40 postmortem studies with total samples under 300 brains across decades, NIH and foundation funded, COI disclosed) highlighted how small available sample sizes have led to inconsistent results and limited statistical power.

Synthesizing a second source, a 2019 survey study published in Autism Research (observational, n=1,134 stakeholders including families and clinicians, no COI reported) found that while 70% of autism community members supported donation in principle, only 12% knew how to arrange it or that programs existed. This aligns with the newer data and reveals a persistent pattern: unlike Alzheimer's research, where public campaigns in the 1990s increased brain donations by an estimated 25-40% according to Alzheimer's Association tracking, autism is often viewed as non-life-threatening, reducing perceived urgency for postmortem donation.

A third source, a 2022 neuropathology paper in Acta Neuropathologica (observational case-control, n=32 autism brains vs controls, university-led with disclosed industry funding for related work), identified synaptic protein abnormalities but explicitly cautioned that larger, more diverse cohorts are desperately needed. The original article also overlooked logistical, cultural, and emotional barriers: grief, religious beliefs, and lack of proactive discussion by physicians compound the awareness problem.

This under-the-radar issue connects to broader patterns in neuroscience where tissue scarcity creates a feedback loop—limited samples slow discovery, which in turn reduces public understanding of why donations matter. Targeted education integrated with autism acceptance initiatives could break this cycle, transforming passive support into concrete contributions that accelerate identification of biological subtypes and potential interventions.